Compile Data Set for Download or QSAR
Report error Found 131 Enz. Inhib. hit(s) with all data for entry = 12377
TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699175(US20240327430, Example 14 | US12145945, Example 14)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699176(US20240327430, Example 15 | US12145945, Example 15)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699173(US20240327430, Example 12 | US12145945, Example 12)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699174(US20240327430, Example 13 | US12145945, Example 13)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699171(US20240327430, Example 10 | US12145945, Example 10)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699172(US20240327430, Example 11 | US12145945, Example 11)
Affinity DataIC50: 100nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699199(US20240327430, Example 39)
Affinity DataIC50: 550nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699200(US20240327430, Example 40 | US12145945, Example 40)
Affinity DataIC50: 550nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699195(2′-chloro-5′-methoxy-6-methyl-N-[6-(2-...)
Affinity DataIC50: 550nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699273(2'-chloro-N-(5-ethoxy-1,3- benzothiazol-2-yl)-5'-m...)
Affinity DataIC50: 550nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699274(2'-chloro-5'-methoxy-6-methyl-N-{5-[2- (trifluorom...)
Affinity DataIC50: 550nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699272(2'-chloro-N-{5-[(1,1-dioxo-1-6-thietan- 3-yl)metho...)
Affinity DataIC50: 550nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699169(US20240327430, Example 8 | US12145945, Example 8)
Affinity DataIC50: 550nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699170(US20240327430, Example 9 | US12145945, Example 9)
Affinity DataIC50: 550nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699231(US20240327430, Example 71 | US12145945, Example 71)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699232(US20240327430, Example 72 | US12145945, Example 72)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699229(US20240327430, Example 69 | US12145945, Example 69)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699230(US20240327430, Example 70 | US12145945, Example 70)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699227(US20240327430, Example 67 | US12145945, Example 67)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699192(BDBM699228 | US20240327430, Example 33)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699225(US20240327430, Example 65 | US12145945, Example 65)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699226(US20240327430, Example 66 | US12145945, Example 66)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699239(US20240327430, Example 79 | US12145945, Example 79)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699240(US20240327430, Example 80 | US12145945, Example 80)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699237(US20240327430, Example 77 | US12145945, Example 77)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699238(US20240327430, Example 78 | US12145945, Example 78)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699235(US20240327430, Example 75 | US12145945, Example 75)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699236(US20240327430, Example 76 | US12145945, Example 76)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699233(US20240327430, Example 73 | US12145945, Example 73)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699234(US20240327430, Example 74 | US12145945, Example 74)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699215(US20240327430, Example 55 | US12145945, Example 55)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699216(US20240327430, Example 56 | US12145945, Example 56)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699213(US20240327430, Example 53 | US12145945, Example 53)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699214(Synthesis of 2′-chloro-N-(5-{3,8-diazabicycl...)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699211(US20240327430, Example 51 | US12145945, Example 51)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699212(US20240327430, Example 52 | US12145945, Example 52)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699209(US20240327430, Example 49 | US12145945, Example 49)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699210(US20240327430, Example 50 | US12145945, Example 50)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699223(US20240327430, Example 63 | US12145945, Example 63)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699224(US20240327430, Example 64 | US12145945, Example 64)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699221(US20240327430, Example 61 | US12145945, Example 61)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699222(US20240327430, Example 62 | US12145945, Example 62)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699219(US20240327430, Example 59 | US12145945, Example 59)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699220(US20240327430, Example 60 | US12145945, Example 60)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699217(US20240327430, Example 57 | US12145945, Example 57)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699218(Synthesis of 2′-chloro-5′-methoxy-6-me...)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699263(2'-chloro-N-{5-[(dimethylcarbamoyl) difluoromethox...)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699264(2'-chloro-5'-methoxy-6-methyl-N-[5- (methylcarbamo...)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699261(2'-chloro-N-{5- [difluoro(methylcarbamoyl) Methoxy...)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

TargetDNA polymerase theta(Human)
Breakpoint Therapeutics

US Patent
LigandPNGBDBM699262(N-(5-bromo-1,3-benzothiazol- 2-yl)-2'-chloro-5'-me...)
Affinity DataIC50: 1.00E+3nMAssay Description:The Polθ ATPase assay was used to evaluate inhibitors of Polθ ATPase activity, in vitro. Experiments were performed using a truncated Pol&#...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/3/2025
Entry Details
Go to US Patent

Displayed 1 to 50 (of 131 total ) | Next | Last >>
Jump to: